Crenotherapy modulates the expression of proinflammatory cytokines and immunoregulatory peptides in nasal secretions of children with chronic rhinosinusitis

American Journal of Rhinology and Allergy

Volumn 26, Issue 1, 2012, Pages

  Passariello, Annalisa ^a,b   Di Costanzo, Margherita ^a   Terrin, Gianluca ^c   Iannotti, Antonio ^d   Buono, Pietro ^a,e   Balestrieri, Umberto ^d   Balestrieri, Gianni ^d   Ascione, Enrico ^d   Pedata, Monica ^a   Canani, Francesco Berni ^f   Canani, Roberto Berni ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b AORN Monaldi   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Otolaryngology and Thermal Medicine   (Italy)

^e Rizzoli Hospital   (Italy)

^f MAGGIORE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; BETA DEFENSIN 2; CALGRANULIN; SULFATE SODIUM CHLORIDE WATER; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AEROSOL; ARTICLE; CHILD; CONTROLLED STUDY; COUGHING; CRENOTHERAPY; CYTOKINE RELEASE; FACE PAIN; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NOSE MUCOSA; NOSE OBSTRUCTION; NOSE SECRETION; OUTCOME ASSESSMENT; PHARMACEUTICAL CARE; PRESCHOOL CHILD; PROSPECTIVE STUDY; PROTEIN EXPRESSION; QUALITY OF LIFE; RHINOSINUSITIS; SCHOOL CHILD; SCORING SYSTEM; SMELLING;

BALNEOLOGY; BETA-DEFENSINS; CHILD, PRESCHOOL; CHRONIC DISEASE; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOMODULATION; INFLAMMATION MEDIATORS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MINERAL WATERS; NASAL MUCOSA; NASAL SPRAYS; QUALITY OF LIFE; RHINITIS; SINUSITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84857708536     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2012.26.3733     Document Type: Article

References (34)

1. Kuehnemund M, Ismail C, Brieger J, et al. Untreated chronic rhinosinusitis: A comparison of symptoms and mediator profiles. Laryngoscope 114:561-565, 2004. (Pubitemid 38391925)
2. Tieu DD, Kern RC, and Schleimer RP. Alterations in epithelial barrier function and host defense responses in chronic rhinosinusitis. J Allergy Clin Immunol 124:37-42, 2009.
3. Coffinet L, Chan KH, Abzug MJ, et al. Immunopathology of chronic rhinosinusitis in young children. J Pediatr 154:754-758, 2009.
4. Halayko AJ, and Ghavami S. S100A8/A9: A mediator of severe asthma pathogenesis and morbidity? Can J Physiol Pharmacol 87: 743-755, 2009.
5. Cheng P, Corzo CA, Luetteke N, et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med 205:2235-2249, 2008.
6. Foell D, Wittkowski H, Ren Z, et al. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J Pathol 216:183-192, 2008.
7. Berni Canani R, Terrin G, Rapacciuolo L, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis 40:547-553, 2008.
8. Sutherland AD, Gearry RB, and Frizelle FA. Review of fecal biomarkers in inflammatory bowel disease. Dis Colon Rectum 51:1283-1291, 2008.
9. Golden BE, Clohessy PA, Russell G, et al. Calprotectin as a marker of inflammation in cystic fibrosis. Arch Dis Child 74:136-139, 1996. (Pubitemid 26057695)
10. Baillet A. S100A8, S100A9, and S100A12 proteins in rheumatoid arthritis. Rev Med Interne 31:458-461, 2010.
11. Berni Canani R, Rapacciuolo L, Romano MT, et al. Diagnostic value of fecal calprotectin in pediatric clinical practice. Dig Liver Dis 36: 467-470, 2004. (Pubitemid 41115450)
12. Doss M, White MR, Tecle T, et al. Human defensins and LL-37 in mucosal immunity. J Leukoc Biol 87:79-92, 2010.
13. Jäger S, Stange EF, and Wehkamp J. Antimicrobial peptides in gastrointestinal inflammation. Int J Inflam, 2010. (Epub ahead of print November 25, 2010.)
14. Yang D, Chertov O, Bykovskaia SN, et al. Beta-defensins: Linking innate and adaptive immunity through dendritic and T cell CCR6. Science 286:525-528, 1999.
15. Niyonsaba F, Ogawa H, and Nagaoka I. Human beta-defensin-2 functions as a chemotactic agent for tumour necrosis factor-alpha-treated human neutrophils. Immunology 111:273-281, 2004. (Pubitemid 38365749)
16. Kapel N, Benahmed N, Morali A, et al. Fecal beta-defensin-2 in children with inflammatory bowel diseases. J Pediatr Gastroenterol Nutr 48:117-120, 2009.
17. Hiratsuka T, Mukae H, Iiboshi H, et al. Increased concentrations of human beta-defensins in plasma and bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis. Thorax 58:425-430, 2003. (Pubitemid 36560946)
18. Ross DJ, Cole AM, Yoshioka D, et al. Increased bronchoalveolar lavage human beta-defensin type 2 in bronchiolitis obliterans syndrome after lung transplantation. Transplantation 78:1222-1224, 2004. (Pubitemid 39426444)
19. Ishimoto H, Mukae H, Date Y, et al. Identification of hBD-3 in respiratory tract and serum: The increase in pneumonia. Eur. Respir. J. 27:253-260, 2006. (Pubitemid 43180899)
20. Vaccarezza M, and Vitale M. Crenotherapy: A neglected resource for human health now re-emerging on sound scientific concepts. Int J Biometeorol 54:491-493, 2010.
21. Staffieri A, and Abramo A. Sulphurous-arsenical-ferruginous (thermal) water inhalations reduce nasal respiratory resistance and improve mucociliary clearance in patients with chronic sinonasal disease: Preliminary outcomes. Acta Otolaryngol 127:613-617, 2007. (Pubitemid 46763704)
22. Staffieri A, Marino F, Staffieri C, et al. The effects of sulfurous-arsenical-ferruginous thermal water nasal irrigation in wound healing after functional endoscopic sinus surgery for chronic rhinosinusitis: A prospective randomized study. Am J Otolaryngol 29:223-229, 2008.
23. Passali D, Lauriello M, Passali GC, et al. Clinical evaluation of the efficacy of Salsomaggiore (Italy) thermal water in the treatment of rhinosinusal pathologies. Clin Ter 159:181-188, 2008. (Pubitemid 352007553)
24. Passali FM, Crisanti A, Passali GC, et al. Efficacy of inhalation therapy with water of Salsomaggiore (Italy) in chronic and recurrent nasosinusal inflammation treatment. Clin Ter 159:175-180, 2008. (Pubitemid 352007552)
25. Ottaviano G, Marioni G, Staffieri C, et al. Effects of sulfurous, salty, bromic, iodic thermal water nasal irrigations in nonallergic chronic rhinosinusitis: A prospective, randomized, double-blind, clinical, and cytological study. Am J Otolaryngol 32:235-239, 2011.
26. Salami A, Dellepiane M, Strinati F, et al. Sulphurous thermal water inhalations in the treatment of chronic rhinosinusitis. Rhinology 48: 71-76, 2010.
27. Leo G, Incorvaia C, Masieri S, et al. Imaging criteria for diagnosis of chronic rhinosinusitis in children. Eur Ann Allergy Clin Immunol 42:199-204, 2010.
28. Kay DJ, and Rosenfeld RM. Quality of life for children with persistent sinonasal symptoms. Otolaryngol Head Neck Surg 128:17-26, 2003. (Pubitemid 36246114)
29. Ciprandi G, Tosca MA, Milanese M, et al. Cytokines evaluation in nasal lavage of allergic children after Bacillus clausii administration: A pilot study. Pediatr Allergy Immunol 15:148-151, 2004. (Pubitemid 38480783)
30. Tieu DD, Peters AT, Carter RG, et al. Evidence for diminished levels of epithelial psoriasin and calprotectin in chronic rhinosinusitis. J Allergy Clin Immunol 125:667-675, 2010.
31. Ramanathan M Jr, Lee WK, Spannhake EW, et al. Th2 cytokines associated with chronic rhinosinusitis with polyps down-regulate the antimicrobial immune function of human sinonasal epithelial cells. Am J Rhinol 22:115-121, 2008. (Pubitemid 351570549)
32. Van Zele T, Claeys S, Gevaert P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy 61: 1280-1289, 2006. (Pubitemid 44465587)
33. Van Crombruggen K, Zhang N, Gevaert P, et al. Pathogenesis of chronic rhinosinusitis: Inflammation. J Allergy Clin Immunol 128: 728-732, 2011.
34. Huvenne W, van Bruaene N, Zhang N, et al. Chronic rhinosinusitis with and without nasal polyps: What is the difference? Curr Allergy Asthma Rep 9:213-220, 2009.